Kainos Medicine Inc - ESG Rating & Company Profile powered by AI
The analysis of Kainos Medicine Inc uses data from across the internet as well as from available disclosures by Kainos Medicine Inc. This article contains a questions and answers table about Kainos Medicine Inc. The webpage displays a free Environmental, Social and Governance assessment for Kainos Medicine Inc.
Kainos Medicine Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | Kainos Medicine Inc | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Kainos Medicine Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kainos Medicine Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Kainos Medicine Inc report the average age of the workforce?
Sign up for free to unlockDoes Kainos Medicine Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kainos Medicine Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kainos Medicine Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Kainos Medicine Inc offer flexible work?
Sign up for free to unlockDoes Kainos Medicine Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kainos Medicine Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kainos Medicine Inc conduct supply chain audits?
Sign up for free to unlockDoes Kainos Medicine Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kainos Medicine Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kainos Medicine Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kainos Medicine Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kainos Medicine Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kainos Medicine Inc disclose water use targets?
Sign up for free to unlockDoes Kainos Medicine Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Kainos Medicine Inc have a product recall in the last two years?
Sign up for free to unlockDoes Kainos Medicine Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Kainos Medicine Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kainos Medicine Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kainos Medicine Inc disclose parental leave metrics?
Sign up for free to unlockDoes Kainos Medicine Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kainos Medicine Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kainos Medicine Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kainos Medicine Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kainos Medicine Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kainos Medicine Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kainos Medicine Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Kainos Medicine Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kainos Medicine Inc disclose its waste policy?
Sign up for free to unlockDoes Kainos Medicine Inc report according to TCFD requirements?
Sign up for free to unlockDoes Kainos Medicine Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kainos Medicine Inc disclose energy use targets?
Sign up for free to unlockDoes Kainos Medicine Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kainos Medicine Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kainos Medicine Inc
These potential risks are based on the size, segment and geographies of the company.
Kainos Medicine, Inc. researches and develops various medicines for cancers, and brain and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is also developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia, as well as small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells. In addition, the company is involved in the discovery of a Hepatitis B drug. It has a collaboration agreement with Emmaus Life Sciences, Inc. for the preclinical development of IRAK4 inhibitor as potential anti-cancer drug. Kainos Medicine, Inc. was founded in 2007 and is headquartered in Seongnam, South Korea.